| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2,6-Diaminopyridine does not have a defined pharmacological target as it is a synthetic intermediate and biochemical reagent. The compound is used to synthesize pentamidine derivatives which show antitumor activities and DNA binding activities. It can also be used to synthesize N-monocarbamoyl derivatives with antiviral activity. In medical research, it has been explored for its potential to enhance neurotransmitter release and improve neuromuscular transmission.
|
|---|---|
| ln Vitro |
In vitro studies have shown that 2,6-Diaminopyridine can be used to synthesize pentamidine derivatives which show antitumor activities and DNA binding activities. It can also be used to synthesize N-monocarbamoyl derivatives with antiviral activity. The compound has been explored for its potential to enhance neurotransmitter release.
|
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for 2,6-Diaminopyridine as a therapeutic agent. The compound is used as an intermediate in pharmaceutical synthesis. It has been explored for treating Lambert-Eaton myasthenic syndrome. Its derivatives and the compounds synthesized from it may be evaluated in animal models.
|
| Enzyme Assay |
For non-cellular assays, 2,6-Diaminopyridine is characterized by standard analytical techniques including HPLC, NMR, and mass spectrometry to confirm identity and purity. The compound has a molecular weight of 109.13 and formula C₅H₇N₃. Storage: keep in a cool, dry place protected from light and moisture. The compound appears as a light gray crystalline powder.
|
| Cell Assay |
For in vitro cell-based studies, 2,6-Diaminopyridine can be used to study neurotransmitter release and neuromuscular transmission. Cells are cultured under standard conditions and treated with the compound to evaluate effects on neurotransmitter release. The compound is typically dissolved in aqueous buffers and diluted in cell culture medium. Appropriate controls should be included in the experimental design.
|
| Animal Protocol |
For in vivo animal studies, 2,6-Diaminopyridine can be formulated using standard injection vehicles. The compound is a solid at room temperature. Dosing solutions should be freshly prepared and administered according to specific protocols with appropriate control groups. Standard handling procedures for pyridine derivatives should be followed.
|
| ADME/Pharmacokinetics |
2,6-Diaminopyridine has a molecular weight of 109.13 and formula C₅H₇N₃. Storage: keep in a cool, dry place protected from light and moisture. The compound appears as a light gray crystalline powder. Purity: typically ≥95-98%. Solubility: soluble in water and organic solvents.
|
| Toxicity/Toxicokinetics |
2,6-Diaminopyridine is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD₅₀ values and detailed toxicological profiles have not been extensively reported.
|
| Additional Infomation |
Structure in the first source
2,6-Diaminopyridine (CAS 141-86-6) is also known as 2,6-pyridinediamine and DAP. It is used to synthesize pentamidine derivatives with antitumor activities and N-monocarbamoyl derivatives with antiviral activity. It is used as an intermediate in pharmaceuticals, dyes, and polymers. No clinical trials or therapeutic approvals exist for the parent compound. |
| Molecular Formula |
C5H7N3
|
|---|---|
| Molecular Weight |
109.13
|
| Exact Mass |
109.063
|
| CAS # |
141-86-6
|
| Related CAS # |
25168-43-8
|
| PubChem CID |
8861
|
| Appearance |
Light brown to gray solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
285.0±0.0 °C at 760 mmHg
|
| Melting Point |
117-122 °C(lit.)
|
| Flash Point |
161.3±9.5 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.676
|
| LogP |
0.55
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
66.1
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=NC(=C1)N)N
|
| InChi Key |
VHNQIURBCCNWDN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H7N3/c6-4-2-1-3-5(7)8-4/h1-3H,(H4,6,7,8)
|
| Chemical Name |
pyridine-2,6-diamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.1634 mL | 45.8169 mL | 91.6338 mL | |
| 5 mM | 1.8327 mL | 9.1634 mL | 18.3268 mL | |
| 10 mM | 0.9163 mL | 4.5817 mL | 9.1634 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
